01—Abstract
Summary
Summary of the 10-Q filed October 31, 2024. Cited figures are marked; the original filing is the authoritative source.
The Cigna Group (CI) reported total revenues of $63.7 billiona for the third quarter of 2024, a significant increase of 30% year-over-year, driven by robust growth in its Evernorth Health Services segment.
Shareholders' net income for the quarter was $739 millionb, or $2.63 per diluted share, a decrease of 48% compared to the prior year, primarily due to a substantial impairment loss on equity securities related to its investment in VillageMD. Despite the decline in net income, adjusted income from operations, a non-GAAP measure that excludes special items like investment losses, increased by 5% to $2.1 billion, signaling underlying operational strength. The company's medical customer base saw a slight decrease of 3%, primarily impacting the Individual and Family Plans within the U.S. Healthcare segment.
However, Evernorth's Pharmacy Benefit Services and Specialty and Care Services segments demonstrated strong revenue growth, supported by increased prescription drug utilization and customer expansion. The company is also advancing its strategic divestiture of its Medicare Advantage business, expected to close in the first quarter of 2025.
02—Key points
Key Highlights
- Total revenues surged 30% year-over-year to $63.7 billion, largely driven by a 36% increase in Evernorth Health Services revenue.
- Shareholders' net income declined 48% to $739 million, significantly impacted by a $2.7 billion impairment loss on its VillageMD equity investment.
- Adjusted income from operations, excluding special items, grew 5% to $2.1 billion, indicating operational resilience.
- Pharmacy and other service costs increased 41% to $47.6 billion, mirroring the revenue growth driven by higher prescription drug utilization.
- The company has entered into an agreement to sell its Medicare Advantage and related businesses to Health Care Service Corporation (HCSC) for approximately $3.7 billion, with an expected closing in Q1 2025.
- Selling, general, and administrative expenses decreased by 5% for the quarter, attributed to the absence of litigation settlements seen in the prior year's quarter.
- The company repurchased approximately $5.0 billion of common stock during the first nine months of 2024, including $3.2 billion under Accelerated Share Repurchase agreements.
03—One dollar
Follow one dollar
Of each $1.00 of revenue in Q3 FY2024, Cigna Group kept $0.01.
- Revenue$63.69B100.0%
- Cost of revenue−$47.56B74.7%
- Gross profit$16.13B25.3%
- Operating costs−$13.55B21.3%
- Operating income$2.58B4.0%
- Interest, other & tax−$1.84B2.9%
- Net income$739.0M1.2%
04—Financials
Financial Highlights
Figures from 10-QQ3 FY2024filed October 31, 2024Financial Statements
Q3 FY2024 against Q3 FY2023
| Line item | Q3 FY2024Q3 FY2023 | Change |
|---|---|---|
| Revenue | $63.69B$49.05B | +29.9% |
| Cost of Revenue | $47.56B$33.64B | +41.4% |
| Gross Profit | $16.13B$15.41B | +4.7% |
| SG&A Expenses | $3.59B$3.79B | −5.2% |
| Operating Income | $2.58B$2.24B | +15.0% |
| Interest Expense | $380.00M$353.00M | +7.6% |
| Net Income | $739.00M$1.41B | −47.5% |
| EPS (Basic) | $2.65$4.79 | −44.7% |
| EPS (Diluted) | $2.63$4.74 | −44.5% |
| Shares Outstanding (Diluted) | 281.40M297.13M | −5.3% |
05—Questions
Frequently Asked Questions
What was the primary driver of the significant year-over-year decline in net income?
The primary driver for the 48% decrease in shareholders' net income was a substantial $2.7 billion impairment loss recognized on the company's investment in VillageMD equity securities. This item is excluded from the adjusted income from operations.
How did the company's revenue performance compare between its main business segments?
The Evernorth Health Services segment showed exceptionally strong revenue growth, increasing by 36% year-over-year, largely due to higher prescription drug utilization and customer expansion. The Cigna Healthcare segment experienced more modest revenue growth of 3%, driven by premium rate increases to cover rising medical costs.
What is the status of the planned sale of the Medicare Advantage business?
Cigna Group has entered into a definitive agreement to sell its Medicare Advantage, Medicare Stand-Alone Prescription Drug Plans, Medicare and Other Supplemental Benefits, and CareAllies businesses to Health Care Service Corporation (HCSC). The transaction is expected to close in the first quarter of 2025 and is valued at approximately $3.7 billion.
What impact did rising interest rates have on the company's financial position?
Rising interest rates increased the fair value of the company's long-term debt. A 100 basis point increase in interest rates would lead to an approximate $2.1 billion decrease in the fair value of long-term debt. However, the company's debt covenants were in compliance as of September 30, 2024.
06—Continue